Glaxosmithkline Biologicals Sa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Jv Bio Srl

Alessandra Vitelli

Alfredo Nicosia

Riccardo Cortese

Virginia Ammendola

Stefano Colloca

Alessandra Luzzago

Ventzislav Bojidarov Vassilev

Benjamin Wizel

Fabiana Grazioli

Jean-Francois Toussaint

Ann-Muriel Steff

Babak Bayat

Clarisse Lorin

Ricardo Cortese

The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

Hepatitis B immunization regimen and compositions

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

Expression systems

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

Immunogenic combinations

Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.

Replication competent adenoviral vectors

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:

Adenovirus polynucleotides and polypeptides

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.

Growing community of inventors

Rome, Italy

Alessandra Vitelli